Literature DB >> 31407112

Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow.

M A Baertsch1, R Lutz2, M S Raab2,3, N Weinhold2, H Goldschmidt2,4.   

Abstract

PURPOSE: The 7th Heidelberg Myeloma Workshop was held on April 5th and 6th, 2019 at the University Hospital Heidelberg. METHODS AND
RESULTS: Main topics of the meeting were (1) diagnostics and prognostic factors, (2) role of immunotherapy in multiple myeloma (MM), (3) current therapy of MM, (4) biology and genomics of MM as well as (5) novel treatment concepts. A debate on the status of minimal residual disease (MRD) driven therapy was held.
CONCLUSION: Diagnostics and treatment of newly diagnosed and relapsed MM are continuously evolving. While advances in the field of (single cell) genetic analysis now allow for characterization of the disease at an unprecedented resolution, immunotherapeutic approaches and MRD testing are at the forefront of the current clinical trial landscape.

Entities:  

Keywords:  Immunotherapy; Minimal residual disease; Multiple myeloma; Single-cell sequencing

Mesh:

Year:  2019        PMID: 31407112     DOI: 10.1007/s00432-019-02998-w

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  40 in total

1.  Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

Authors:  Meletios A Dimopoulos; Dominik Dytfeld; Sebastian Grosicki; Philippe Moreau; Naoki Takezako; Mitsuo Hori; Xavier Leleu; Richard LeBlanc; Kenshi Suzuki; Marc S Raab; Paul G Richardson; Mihaela Popa McKiver; Ying-Ming Jou; Suresh G Shelat; Michael Robbins; Brian Rafferty; Jesús San-Miguel
Journal:  N Engl J Med       Date:  2018-11-08       Impact factor: 91.245

2.  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Authors:  Meletios A Dimopoulos; Albert Oriol; Hareth Nahi; Jesus San-Miguel; Nizar J Bahlis; Saad Z Usmani; Neil Rabin; Robert Z Orlowski; Mieczyslaw Komarnicki; Kenshi Suzuki; Torben Plesner; Sung-Soo Yoon; Dina Ben Yehuda; Paul G Richardson; Hartmut Goldschmidt; Donna Reece; Steen Lisby; Nushmia Z Khokhar; Lisa O'Rourke; Christopher Chiu; Xiang Qin; Mary Guckert; Tahamtan Ahmadi; Philippe Moreau
Journal:  N Engl J Med       Date:  2016-10-06       Impact factor: 91.245

Review 3.  International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Authors:  Jens Hillengass; Saad Usmani; S Vincent Rajkumar; Brian G M Durie; María-Victoria Mateos; Sagar Lonial; Cristina Joao; Kenneth C Anderson; Ramón García-Sanz; Eloísa Riva; Juan Du; Niels van de Donk; Jesús G Berdeja; Evangelos Terpos; Elena Zamagni; Robert A Kyle; Jesús San Miguel; Hartmut Goldschmidt; Sergio Giralt; Shaji Kumar; Noopur Raje; Heinz Ludwig; Enrique Ocio; Rik Schots; Hermann Einsele; Fredrik Schjesvold; Wen-Ming Chen; Niels Abildgaard; Brea C Lipe; Dominik Dytfeld; Baldeep Mona Wirk; Matthew Drake; Michele Cavo; Juan José Lahuerta; Suzanne Lentzsch
Journal:  Lancet Oncol       Date:  2019-06       Impact factor: 41.316

4.  International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

Authors:  Meletios A Dimopoulos; Pieter Sonneveld; Nelson Leung; Giampaolo Merlini; Heinz Ludwig; Efstathios Kastritis; Hartmut Goldschmidt; Douglas Joshua; Robert Z Orlowski; Raymond Powles; David H Vesole; Laurent Garderet; Hermann Einsele; Antonio Palumbo; Michele Cavo; Paul G Richardson; Philippe Moreau; Jesús San Miguel; S Vincent Rajkumar; Brian G M Durie; Evangelos Terpos
Journal:  J Clin Oncol       Date:  2016-03-14       Impact factor: 44.544

Review 5.  Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.

Authors:  Morie A Gertz
Journal:  Am J Hematol       Date:  2018-09       Impact factor: 10.047

Review 6.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

7.  Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.

Authors:  Guangwu Guo; Noopur S Raje; Charles Seifer; Jake Kloeber; Randi Isenhart; Gavin Ha; Andrew J Yee; Elizabeth K O'Donnell; Yu-Tzu Tai; Paul G Richardson; Giada Bianchi; Jacob P Laubach; Diane Warren; Erica Gemme; Jordan Voisine; Julia Frede; Antonis Kokkalis; Huiyoung Yun; Valeriya Dimitrova; Tushara Vijaykumar; Matthew Meyerson; Nikhil C Munshi; Kenneth C Anderson; Birgit Knoechel; Jens G Lohr
Journal:  Leukemia       Date:  2018-03-27       Impact factor: 11.528

8.  Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.

Authors:  Meletios A Dimopoulos; Jesus San-Miguel; Andrew Belch; Darrell White; Lotfi Benboubker; Gordon Cook; Merav Leiba; James Morton; P Joy Ho; Kihyun Kim; Naoki Takezako; Philippe Moreau; Jonathan L Kaufman; Heather J Sutherland; Marc Lalancette; Hila Magen; Shinsuke Iida; Jin Seok Kim; H Miles Prince; Tara Cochrane; Albert Oriol; Nizar J Bahlis; Ajai Chari; Lisa O'Rourke; Kaida Wu; Jordan M Schecter; Tineke Casneuf; Christopher Chiu; David Soong; A Kate Sasser; Nushmia Z Khokhar; Hervé Avet-Loiseau; Saad Z Usmani
Journal:  Haematologica       Date:  2018-09-20       Impact factor: 9.941

9.  Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.

Authors:  Tobias Dittrich; Axel Benner; Christoph Kimmich; Fabian Aus dem Siepen; Kaya Veelken; Arnt V Kristen; Tilmann Bochtler; Hugo A Katus; Carsten Müller-Tidow; Ute Hegenbart; Stefan O Schönland
Journal:  Haematologica       Date:  2019-01-17       Impact factor: 9.941

10.  Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

Authors:  Arjun Lakshman; S Vincent Rajkumar; Francis K Buadi; Moritz Binder; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; David Dingli; Amie L Fonder; Suzanne R Hayman; Miriam A Hobbs; Wilson I Gonsalves; Yi Lisa Hwa; Prashant Kapoor; Nelson Leung; Ronald S Go; Yi Lin; Taxiarchis V Kourelis; Rahma Warsame; John A Lust; Stephen J Russell; Steven R Zeldenrust; Robert A Kyle; Shaji K Kumar
Journal:  Blood Cancer J       Date:  2018-06-12       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.